A BETTER BALANCE

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has...

On August 14, 2020, the FDA approved Genentech’s EnspryngTM (satralizumab-mwge) as the first and only subcutaneous treatment for adults living...

If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced topline results from its Phase III study program evaluating...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III COVACTA study of Actemra® (tocilizumab)...

In the Archway study, Port Delivery System with ranibizumab (PDS) demonstrated non-inferior and equivalent visual acuity outcomes compared with...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the second interim analysis of the Phase IIIb...

South San Francisco, CA -- July 12, 2020 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has...

IMpassion031 data will be discussed with health authorities globally, including the U.S. Food and Drug Administration and the European Medicines...